查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463764

紅色生物技術的全球市場：市場規模和佔有率分析（依應用、產品和最終用戶）、工業需求預測（截至 2030 年）

Red Biotechnology Market Size and Share Report by Application, Product, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 240 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

主要亮點

預計2023年全球紅色生技市場規模將達5,767億美元，2030年將達1,1723億美元，複合年增長率超過10.5%。

對臨床試驗、藥物發現、帶因者篩檢和診斷的需求不斷增長，以及遺傳疾病盛行率的上升，正在推動產業擴張。

關鍵見解

2023年生物製藥產量將以25.0%的佔有率引領產業，預計未來10年將繼續引領產業。

2023年，人用疫苗將以30.0%的佔有率引領產業，預計未來10年將持續。

到 2023 年，北美地區將以約 55% 的佔有率引領產業，預計未來幾年將呈現更穩定的成長。

亞太地區正以最快的速度取得進展。 這是由於該地區來自國內外生物技術公司的資金不斷增加，以及大量的傳染病和慢性病患者。

本報告分析了全球紅色生物技術市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（以貨幣計算） ，2017-2030），依應用程式、產品和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/課題
    • 促進/抑制因子影響分析
  • 新型冠狀病毒感染 (COVID-19) 的影響
  • 波特五力分析

第六章世界市場

  • 摘要
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

  • 摘要
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依國家/地區劃分（2017-2030 年）

第八章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第十一章中東及非洲市場

第12章美國市場

  • 摘要
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

  • 市場參與者及其提供的產品/服務的列表
  • 主要公司的競爭基準
  • 各大公司的產品基準
  • 近期策略發展狀況

第30章公司簡介

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Regeneron Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Novartis AG

第31章附錄

簡介目錄
Product Code: 12849

Key Highlights

The red biotechnology market generated a value of USD 576.7 billion in 2023, and it will increase to USD 1,172.3 billion, advancing at more than 10.5% compound annual growth rate, by 2030.

The increasing need for it in clinical trials, drug discovery, carrier screening, and diagnostics, along with the rising incidence of genetic disorders aid the industry expansion.

Effective product development as well as genetic engineering relating to new drugs for treating life-threatening ailments are the key benefits of red biotechnology.

The increasing technological advancement rate in gene sequencing platforms, rising investment from private bodies and government for large-scale biotechnology plans, and substantial acceptance of red biotechnology across different applications like veterinary sciences, tissue engineering, and poultry farming, resulted in the industry expansion.

The increasing incidence of cancer and the surging use of this technology in cancer research & diagnostics are major drivers for this industry.

These technologies are employed for producing combination vaccines, including those that target Hepatitis A, Hepatitis B, polio, and diphtheria at once.

The rising count of R&D initiatives by major players, particularly in the area of stem cells, is a major trend in this industry.

Likewise, the pandemic of COVID-19 and a rising count of research studies discovering the use of this method for developing medicines, vaccines, and diagnostic tools assist industry expansion.

Key Insights

Biopharmaceutical production led the industry in 2023, with a 25.0% share, and it will further remain leading throughout this decade.

The increasing need for proteins, antibodies, antisense oligonucleotides, RNA, and DNA for diagnostic and therapeutic purposes is boosting the biopharmaceutical production category growth.

Gene therapy is likely to propel at the fastest compound annual growth rate in the years to come. The increasing incidence of genetic disorders as well as cancers is driving this category.

The human vaccines category led the industry in 2023, with a share of 30.0%, and it will continue this trend throughout this decade.

The human vaccines category growth is because of the increasing occurrence of infectious disease outbreaks and the rising prevalence of chronic ailments.

The biopharmaceutical industry was the largest contributor to the industry in 2023, with a 40.0% share, and it is likely to remain the largest during this decade.

The enhancing biopharmaceutical production infrastructure and R&D globally, to discover new molecule entities & vaccines against infectious ailments is driving the human vaccines category growth.

North America led the industry in 2023, with approximately 55% share, and it will further advance at a robust rate in the years to come.

The dominance of North America is because of the increasing incidence of rare, genetic, and chronic illnesses; the high technological improvement rate in the healthcare sector, and the rising number of R&D initiatives.

APAC is advancing at the fastest rate. This is because of the rising funding from both overseas and domestic biotech firms in this region and an enormous pool of patients with infectious and chronic ailments.

The red biotechnology industry is fragmented in nature, with the significant existence of large-scale companies.

These companies are involved in product launches, new product development, agreements, mergers, partnerships, and product approval to enhance their market presence.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by application
    • 1.4.2. Market size breakdown, by product
    • 1.4.3. Market size breakdown, by end user
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Application (2017-2030)
  • 6.3. Market Revenue, by Product (2017-2030)
  • 6.4. Market Revenue, by End User (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Application (2017-2030)
  • 7.3. Market Revenue, by Product (2017-2030)
  • 7.4. Market Revenue, by End User (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Application (2017-2030)
  • 8.3. Market Revenue, by Product (2017-2030)
  • 8.4. Market Revenue, by End User (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Application (2017-2030)
  • 9.3. Market Revenue, by Product (2017-2030)
  • 9.4. Market Revenue, by End User (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Application (2017-2030)
  • 10.3. Market Revenue, by Product (2017-2030)
  • 10.4. Market Revenue, by End User (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Application (2017-2030)
  • 11.3. Market Revenue, by Product (2017-2030)
  • 11.4. Market Revenue, by End User (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Application (2017-2030)
  • 12.3. Market Revenue, by Product (2017-2030)
  • 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Application (2017-2030)
  • 13.3. Market Revenue, by Product (2017-2030)
  • 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Application (2017-2030)
  • 14.3. Market Revenue, by Product (2017-2030)
  • 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Application (2017-2030)
  • 15.3. Market Revenue, by Product (2017-2030)
  • 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Application (2017-2030)
  • 16.3. Market Revenue, by Product (2017-2030)
  • 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Application (2017-2030)
  • 17.3. Market Revenue, by Product (2017-2030)
  • 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Application (2017-2030)
  • 18.3. Market Revenue, by Product (2017-2030)
  • 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Application (2017-2030)
  • 19.3. Market Revenue, by Product (2017-2030)
  • 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Application (2017-2030)
  • 20.3. Market Revenue, by Product (2017-2030)
  • 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Application (2017-2030)
  • 21.3. Market Revenue, by Product (2017-2030)
  • 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Application (2017-2030)
  • 22.3. Market Revenue, by Product (2017-2030)
  • 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Application (2017-2030)
  • 23.3. Market Revenue, by Product (2017-2030)
  • 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Application (2017-2030)
  • 24.3. Market Revenue, by Product (2017-2030)
  • 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Application (2017-2030)
  • 25.3. Market Revenue, by Product (2017-2030)
  • 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Application (2017-2030)
  • 26.3. Market Revenue, by Product (2017-2030)
  • 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Application (2017-2030)
  • 27.3. Market Revenue, by Product (2017-2030)
  • 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Application (2017-2030)
  • 28.3. Market Revenue, by Product (2017-2030)
  • 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Pfizer Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. F. Hoffmann-La Roche Ltd.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Merck KGaA
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. AstraZeneca PLC
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Takeda Pharmaceutical Company Limited
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Amgen Inc.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Regeneron Pharmaceuticals Inc.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Gilead Sciences Inc.
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Novartis AG
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports